Baxter International Inc (BAX) Stock Analysis

BAX- NYSE (USA) Also traded in: Germany, Mexico, Switzerland, UK
Baxter International Inc

Currently 1/5

Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$48.93

0(0%) Volume: 2,299,506 1:01AM EST

Avg Vol (1m): 3,518,152

Warning! GuruFocus has detected 3 Severe Warning Signs with BAX. Click here to check it out.

Market Cap	26.35 B	P/E(ttm)	5.42
Enterprise Value	25.96 B	P/B	3.10

$48.93 (1y: +33%)

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Also traded in: Germany, Mexico, Switzerland, UK

Financial Strength : 6/10

		vs industry	vs history
Cash to Debt	N/A	BAX's Cash to Debt is ranked higher than 81% of the 190 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 1.50 vs. BAX: N/A ) Ranked among companies with meaningful Cash to Debt only.	BAX' s Cash to Debt Range Over the Past 10 Years Min: 0.17 Med: 0.31 Max: N/A Current: N/A
Equity to Asset	0.55	BAX's Equity to Asset is ranked lower than 55% of the 185 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 0.58 vs. BAX: 0.55 ) Ranked among companies with meaningful Equity to Asset only.	BAX' s Equity to Asset Range Over the Past 10 Years Min: 0.24 Med: 0.34 Max: 0.55 Current: 0.55 0.24 - 0.55
Interest Coverage	8.83	BAX's Interest Coverage is ranked lower than 73% of the 136 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 39.93 vs. BAX: 8.83 ) Ranked among companies with meaningful Interest Coverage only.	BAX' s Interest Coverage Range Over the Past 10 Years Min: 3.08 Med: 17.4 Max: 32.02 Current: 8.83 3.08 - 32.02

WACC vs ROIC

7.08%

7.91%

WACC

ROIC

Profitability & Growth : 3/10

		vs industry	vs history
Operating margin (%)	7.12	BAX's Operating margin (%) is ranked higher than 59% of the 188 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 4.74 vs. BAX: 7.12 ) Ranked among companies with meaningful Operating margin (%) only.	BAX' s Operating margin (%) Range Over the Past 10 Years Min: 4.5 Med: 17.94 Max: 22.9 Current: 7.12 4.5 - 22.9
Net-margin (%)	48.85	BAX's Net-margin (%) is ranked higher than 99% of the 188 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.07 vs. BAX: 48.85 ) Ranked among companies with meaningful Net-margin (%) only.	BAX' s Net-margin (%) Range Over the Past 10 Years Min: 9.71 Med: 16.5 Max: 48.85 Current: 48.85 9.71 - 48.85
ROE (%)	57.90	BAX's ROE (%) is ranked higher than 98% of the 182 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 3.17 vs. BAX: 57.90 ) Ranked among companies with meaningful ROE (%) only.	BAX' s ROE (%) Range Over the Past 10 Years Min: 11.41 Med: 30.38 Max: 112.25 Current: 57.9 11.41 - 112.25
ROA (%)	27.50	BAX's ROA (%) is ranked higher than 98% of the 192 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 1.59 vs. BAX: 27.50 ) Ranked among companies with meaningful ROA (%) only.	BAX' s ROA (%) Range Over the Past 10 Years Min: 4.11 Med: 11.59 Max: 47.34 Current: 27.5 4.11 - 47.34
ROC (Joel Greenblatt) (%)	12.07	BAX's ROC (Joel Greenblatt) (%) is ranked higher than 54% of the 190 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 8.16 vs. BAX: 12.07 ) Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.	BAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years Min: 5.65 Med: 34.46 Max: 43.28 Current: 12.07 5.65 - 43.28
Revenue Growth (3Y)(%)	2.50	BAX's Revenue Growth (3Y)(%) is ranked lower than 54% of the 151 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 4.00 vs. BAX: 2.50 ) Ranked among companies with meaningful Revenue Growth (3Y)(%) only.	BAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years Min: -10.2 Med: 6.7 Max: 17.3 Current: 2.5 -10.2 - 17.3
EBITDA Growth (3Y)(%)	-14.80	BAX's EBITDA Growth (3Y)(%) is ranked lower than 81% of the 127 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 5.70 vs. BAX: -14.80 ) Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.	BAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years Min: -28.3 Med: 6.6 Max: 33.1 Current: -14.8 -28.3 - 33.1
EPS Growth (3Y)(%)	151.00	BAX's EPS Growth (3Y)(%) is ranked higher than 98% of the 121 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 6.00 vs. BAX: 151.00 ) Ranked among companies with meaningful EPS Growth (3Y)(%) only.	BAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years Min: -44 Med: 7.1 Max: 151 Current: 151 -44 - 151

GuruFocus has detected 8 Warning Signs with Baxter International Inc $BAX.

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

» BAX's 10-Y Financials

Financials (Next Earnings Date: 2017-04-26)

Revenue & Net Income

Cash & Debt

Oprt. Cash Flow & Free Cash Flow

Oprt. Cash Flow & Net Income

» BAX's Warning Signs

Warning Signs

Subscribe to see Warning Signs. .

Start your free trial

» Details

Guru Trades

Q1 2016

Q2 2016

Q3 2016

Q4 2016

» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Select Gurus: | Basic | Premium

| Premium Plus

No Entry found in the selected group of Gurus. You can

1. Modify your Personalized List of Gurus, or
2. Click on Premium above to check out all the Gurus, or
3. Click on Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry:	Medical Instruments & Equipment » Medical Instruments & Supplies NAICS: 339112 SIC: 3841
Compare:	OTCPK:ESLOY, NAS:ILMN, NYSE:BCR, OTCPK:CLPBY, NYSE:BDX, OTCPK:TRUMF, NAS:XRAY, OTCPK:OCPNY, NYSE:WAT, NYSE:MTD, NAS:HOLX, NYSE:RMD, NYSE:COO, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NYSE:HRC, OTCPK:GNGBY, NYSE:CMD, OTCPK:ANSLY » details
Traded in other countries:	BTL.Germany, BAX.Mexico, BAX.Switzerland, 0QK8.UK,

Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.

Baxter International Inc was incorporated in Delaware in 1931. The Company is a healthcare company. It is engaged in the development, manufacture and sale of products that save and sustain the lives of people with immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products that advance patient care. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely, Hospital Products and Renal. The Hospital Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. The Renal business also offers a portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis (PD), in-center hemodialysis (HD), home HD (HHD), continuous renal replacement therapy (CRRT) and additional dialysis services. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.

Guru Investment Theses on Baxter International Inc

Bill Nygren Comments on Baxter - Jan 10, 2017

Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund fourth quarter 2016 commentary.

Check out Bill Nygren latest stock trades

Ratios

		vs industry	vs history
P/E(ttm)	5.42	BAX's P/E(ttm) is ranked higher than 96% of the 114 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 29.80 vs. BAX: 5.42 ) Ranked among companies with meaningful P/E(ttm) only.	BAX' s P/E(ttm) Range Over the Past 10 Years Min: 4.88 Med: 9.45 Max: 22.53 Current: 5.42 4.88 - 22.53
Forward P/E	22.73	BAX's Forward P/E is ranked higher than 54% of the 39 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 23.20 vs. BAX: 22.73 ) Ranked among companies with meaningful Forward P/E only.	N/A
PE(NRI)	5.42	BAX's PE(NRI) is ranked higher than 96% of the 115 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 28.54 vs. BAX: 5.42 ) Ranked among companies with meaningful PE(NRI) only.	BAX' s PE(NRI) Range Over the Past 10 Years Min: 4.89 Med: 10.11 Max: 115.67 Current: 5.42 4.89 - 115.67
Price/Owner Earnings (ttm)	6.35	BAX's Price/Owner Earnings (ttm) is ranked higher than 94% of the 84 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 26.09 vs. BAX: 6.35 ) Ranked among companies with meaningful Price/Owner Earnings (ttm) only.	BAX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years Min: 5.66 Med: 11.81 Max: 37.62 Current: 6.35 5.66 - 37.62
P/B	3.10	BAX's P/B is ranked higher than 54% of the 179 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 3.30 vs. BAX: 3.10 ) Ranked among companies with meaningful P/B only.	BAX' s P/B Range Over the Past 10 Years Min: 2.05 Med: 2.62 Max: 3.34 Current: 3.1 2.05 - 3.34
P/S	2.68	BAX's P/S is ranked higher than 51% of the 181 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.82 vs. BAX: 2.68 ) Ranked among companies with meaningful P/S only.	BAX' s P/S Range Over the Past 10 Years Min: 1.06 Med: 1.57 Max: 2.69 Current: 2.68 1.06 - 2.69
PFCF	64.05	BAX's PFCF is ranked lower than 81% of the 77 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 30.29 vs. BAX: 64.05 ) Ranked among companies with meaningful PFCF only.	BAX' s PFCF Range Over the Past 10 Years Min: 6.96 Med: 10.08 Max: 73.66 Current: 64.05 6.96 - 73.66
POCF	28.73	BAX's POCF is ranked lower than 74% of the 97 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 18.53 vs. BAX: 28.73 ) Ranked among companies with meaningful POCF only.	BAX' s POCF Range Over the Past 10 Years Min: 4.58 Med: 7.25 Max: 28.77 Current: 28.73 4.58 - 28.77
EV-to-EBIT	36.18	BAX's EV-to-EBIT is ranked lower than 72% of the 117 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 22.89 vs. BAX: 36.18 ) Ranked among companies with meaningful EV-to-EBIT only.	BAX' s EV-to-EBIT Range Over the Past 10 Years Min: -2940.9 Med: 8.8 Max: 63.8 Current: 36.18 -2940.9 - 63.8
EV-to-EBITDA	19.77	BAX's EV-to-EBITDA is ranked lower than 58% of the 129 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 17.65 vs. BAX: 19.77 ) Ranked among companies with meaningful EV-to-EBITDA only.	BAX' s EV-to-EBITDA Range Over the Past 10 Years Min: 4.4 Med: 6.9 Max: 45.7 Current: 19.77 4.4 - 45.7
Shiller P/E	11.63	BAX's Shiller P/E is ranked higher than 91% of the 47 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 41.25 vs. BAX: 11.63 ) Ranked among companies with meaningful Shiller P/E only.	BAX' s Shiller P/E Range Over the Past 10 Years Min: 9.67 Med: 12.79 Max: 21.71 Current: 11.63 9.67 - 21.71
Days Inventory	98.18	BAX's Days Inventory is ranked higher than 67% of the 174 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 123.20 vs. BAX: 98.18 ) Ranked among companies with meaningful Days Inventory only.	BAX' s Days Inventory Range Over the Past 10 Years Min: 48.36 Med: 138.8 Max: 219.03 Current: 98.18 48.36 - 219.03
Days Sales Outstanding	62.46	BAX's Days Sales Outstanding is ranked higher than 51% of the 154 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 63.06 vs. BAX: 62.46 ) Ranked among companies with meaningful Days Sales Outstanding only.	BAX' s Days Sales Outstanding Range Over the Past 10 Years Min: 58.53 Med: 65.66 Max: 112.88 Current: 62.46 58.53 - 112.88

Dividend & Buy Back

		vs industry	vs history
Dividend Yield	1.03	BAX's Dividend Yield is ranked lower than 59% of the 148 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 1.12 vs. BAX: 1.03 ) Ranked among companies with meaningful Dividend Yield only.	BAX' s Dividend Yield Range Over the Past 10 Years Min: 0.98 Med: 3.84 Max: 5.89 Current: 1.03 0.98 - 5.89
Dividend Payout	0.06	BAX's Dividend Payout is ranked higher than 98% of the 89 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 0.31 vs. BAX: 0.06 ) Ranked among companies with meaningful Dividend Payout only.	BAX' s Dividend Payout Range Over the Past 10 Years Min: 0.06 Med: 0.35 Max: 3.37 Current: 0.06 0.06 - 3.37
Dividend Growth (3y)	-35.90	BAX's Dividend Growth (3y) is ranked lower than 88% of the 64 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 10.90 vs. BAX: -35.90 ) Ranked among companies with meaningful Dividend Growth (3y) only.	BAX' s Dividend Growth (3y) Range Over the Past 10 Years Min: -35.9 Med: 0.8 Max: 22.5 Current: -35.9 -35.9 - 22.5
Forward Dividend Yield	1.08	BAX's Forward Dividend Yield is ranked lower than 57% of the 144 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 1.41 vs. BAX: 1.08 ) Ranked among companies with meaningful Forward Dividend Yield only.	N/A
Yield on cost (5-Year)	0.49	BAX's Yield on cost (5-Year) is ranked lower than 71% of the 167 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 1.95 vs. BAX: 0.49 ) Ranked among companies with meaningful Yield on cost (5-Year) only.	BAX' s Yield on cost (5-Year) Range Over the Past 10 Years Min: 0.47 Med: 1.84 Max: 2.82 Current: 0.49 0.47 - 2.82
3-Year Average Share Buyback Ratio	0.30	BAX's 3-Year Average Share Buyback Ratio is ranked higher than 84% of the 122 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: -2.70 vs. BAX: 0.30 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.	BAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years Min: -2.1 Med: -0.1 Max: 3.3 Current: 0.3 -2.1 - 3.3

Valuation & Return

		vs industry	vs history
Price/Tangible Book	5.52	BAX's Price/Tangible Book is ranked lower than 55% of the 154 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 4.63 vs. BAX: 5.52 ) Ranked among companies with meaningful Price/Tangible Book only.	BAX' s Price/Tangible Book Range Over the Past 10 Years Min: 3.9 Med: 5.46 Max: 10.45 Current: 5.52 3.9 - 10.45
Price/Projected FCF	1.74	BAX's Price/Projected FCF is ranked lower than 99.99% of the 79 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.03 vs. BAX: 1.74 ) Ranked among companies with meaningful Price/Projected FCF only.	BAX' s Price/Projected FCF Range Over the Past 10 Years Min: 0 Med: 1.03 Max: 2.34 Current: 1.74 0 - 2.34
Price/Median PS Value	1.69	BAX's Price/Median PS Value is ranked lower than 99.99% of the 150 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 1.10 vs. BAX: 1.69 ) Ranked among companies with meaningful Price/Median PS Value only.	BAX' s Price/Median PS Value Range Over the Past 10 Years Min: 0 Med: 0.96 Max: 1.69 Current: 1.69 0 - 1.69
Price/Graham Number	1.16	BAX's Price/Graham Number is ranked lower than 99.99% of the 86 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.40 vs. BAX: 1.16 ) Ranked among companies with meaningful Price/Graham Number only.	BAX' s Price/Graham Number Range Over the Past 10 Years Min: 0 Med: 2.01 Max: 5.55 Current: 1.16 0 - 5.55
Earnings Yield (Greenblatt) (%)	2.75	BAX's Earnings Yield (Greenblatt) (%) is ranked higher than 56% of the 189 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 2.20 vs. BAX: 2.75 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.	BAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years Min: 1.6 Med: 11.3 Max: 19.9 Current: 2.75 1.6 - 19.9
Forward Rate of Return (Yacktman) (%)	-1.85	BAX's Forward Rate of Return (Yacktman) (%) is ranked lower than 77% of the 91 Companies in the Global Medical Instruments & Supplies industry. ( Industry Median: 8.90 vs. BAX: -1.85 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.	BAX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years Min: -11.9 Med: 15.6 Max: 30.5 Current: -1.85 -11.9 - 30.5

More Statistics

Revenue (TTM) (Mil) $	10,163
EPS (TTM) $	9.01
Beta	0.70
Short Percentage of Float	1.60%
52-Week Range $	35.74 - 50.16
Shares Outstanding (Mil)	538.52

Analyst Estimate

	Dec17	Dec18	Dec19
Revenue (Mil $)	10,293	10,710	10,883
EPS ($)	2.11	2.40	2.56
EPS w/o NRI ($)	2.11	2.40	2.56
EPS Growth Rate (3Y to 5Y Estimate)	17.86%
Dividends Per Share ($)	0.61	0.61	0.67

» More Articles for BAX

Headlines

Articles On GuruFocus.com

Edwards Lifesciences Director Buys 3,000 Shares Feb 07 2017

Using a Benjamin Graham Value Investing Strategy Feb 07 2017

Daniel Loeb's Third Point Hedge Fund 4th Quarter Commentary Feb 02 2017

10 Low P/E Stock Picks for the Defensive Investor Jan 30 2017

4 Best Stocks for Value Investors This Week Jan 29 2017

Steven Romick Spots Next Area of Interest, Health Care Jan 13 2017

Bill Nygren Comments on Baxter Jan 10 2017

10 Stocks Trading Below Their Graham Number Dec 19 2016

10 Undervalued Stocks for the Defensive Investor Dec 15 2016

10 Stocks for Using a Benjamin Graham Value Investing Strategy Dec 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

Value Screens

Downloads | Tools

Strategies

Market Valuation

By Country

Articles

Submit Articles

Financial Strength : 6/10

Profitability & Growth : 3/10

Financials (Next Earnings Date: 2017-04-26)

Warning Signs

Guru Trades

BAX Guru Trades in Q1 2016

BAX Guru Trades in Q2 2016

BAX Guru Trades in Q3 2016

BAX Guru Trades in Q4 2016

Insider Trades

Latest Guru Trades with BAX

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Guru Investment Theses on Baxter International Inc

Bill Nygren Comments on Baxter - Jan 10, 2017

Top Ranked Articles about Baxter International Inc

Ratios

Dividend & Buy Back

Valuation & Return

More Statistics

Analyst Estimate

Headlines

Personalized Checklist

Value Screens

Downloads | Tools

Strategies

Market Valuation

By Country

Articles

Submit Articles

Financial Strength : 6/10

Profitability & Growth : 3/10

Financials .earnings_date { color: #000000; font-size: 12px; font-weight: normal; } (Next Earnings Date: 2017-04-26)

Warning Signs

Guru Trades

BAX Guru Trades in Q1 2016

BAX Guru Trades in Q2 2016

BAX Guru Trades in Q3 2016

BAX Guru Trades in Q4 2016

Insider Trades

Latest Guru Trades with BAX

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Guru Investment Theses on Baxter International Inc

Bill Nygren Comments on Baxter - Jan 10, 2017

Top Ranked Articles about Baxter International Inc

Ratios

Dividend & Buy Back

Valuation & Return

More Statistics

Analyst Estimate

Headlines

Personalized Checklist

Financials (Next Earnings Date: 2017-04-26)